IIROC Trade Resumption - NIRV

IIROC Trade Resumption - NIRV

Trading resumes in:

Company: Nirvana Life Sciences Inc.

CSE Symbol: NIRV

All Issues: Yes

Resumption (ET): 1:30 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

Cision View original content: https://www.newswire.ca/en/releases/archive/June2022/02/c9971.html

News Provided by Canada Newswire via QuoteMedia

cse:nirvpsychedelics investing
NIRV:CC
The Conversation (0)
Nirvana Life Sciences

Nirvana Life Sciences

Psychedelics for Opioid Addiction Recovery and Pain Management

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it... Keep Reading...
Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.Mr.... Keep Reading...
Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h. Nirvana... Keep Reading...
Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds

Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines and formulations to be used in trauma work,... Keep Reading...
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs

Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive... Keep Reading...
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks. While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and... Keep Reading...

Latest News

Latest Press Releases

Locksley Reports High-Grade Antimony Concentrate at Significantly Higher Grades than Comparable American Projects in Initial Metallurgical Test Work of Surface Samples from the Company's Desert Antimony Mine Project in California

Homerun Resources Inc. Announces Future Production of 100% Antimony-Free Solar Glass in Brazil

Golconda Gold Ltd. Releases Q3 2025 Production Update

Kobo Resources Intersects 17.0 m at 3.87 g/t Au, Further Defining High-Grade Gold Mineralisation at its Kossou Gold Project

Related News

lithium investing

Saskatchewan Implements New Lithium Royalty

Precious Metals Investing

Locksley Reports High-Grade Antimony Concentrate at Significantly Higher Grades than Comparable American Projects in Initial Metallurgical Test Work of Surface Samples from the Company's Desert Antimony Mine Project in California

Tech Investing

Homerun Resources Inc. Announces Future Production of 100% Antimony-Free Solar Glass in Brazil

Precious Metals Investing

Golconda Gold Ltd. Releases Q3 2025 Production Update

Precious Metals Investing

Kobo Resources Intersects 17.0 m at 3.87 g/t Au, Further Defining High-Grade Gold Mineralisation at its Kossou Gold Project

Copper Investing

Canada One Mining: Positioned for Significant Copper Discovery in  British Columbia

Precious Metals Investing

Locksley Produces High Grade Antimony Concentrate